Placenta-Targeted Nanoparticles: A New Frontier in Recurrent Pregnancy Loss – Reproduction and Fertility
Reproduction and Fertility shared a post on LinkedIn:
“Day 4 of RaFJC – Placenta-Targeted Nanoparticles: A New Frontier in Recurrent Pregnancy Loss (RPL)
Recurrent pregnancy loss (RPL) (two or more consecutive miscarriages) affects 1–2% of couples worldwide. Up to 50% of cases remain unexplained, with immune maladaptation at the maternal–fetal interface increasingly recognised as a key driver.
Current therapies rely on systemic immunosuppression (corticosteroids, IVIG, TNF inhibitors), which:
- Show inconsistent efficacy
- Carry significant risks
- Are costly and not always accessible
This highlights the urgent need for localised, safer, and cost‑effective therapies.
Mohsen Dashti, Vinnie A., and Mehdi Yousefi propose a placenta‑targeted nanoparticle (NP) system for localized immune cloaking.
Core design:
- PLGA biodegradable matrix
- Lipid‑PEG stealth layer to prolong circulation
- SPIONs for imaging and tracking
- Placental‑homing peptides for site‑specific delivery
Evidence so far:
- Rodent and primate models show placenta‑specific NP delivery is feasible
- NPs can induce anti‑inflammatory cytokines, suppress cytotoxic NK/T cells, and remodel spiral arteries
- Ex vivo human placenta models confirm uptake with minimal fetal exposure
Estimated cost: $0.56–$5.58 per dose, far cheaper than IVIG or biologics. Production is scalable.
In conclusion, placenta‑targeted nanoparticles represent a promising therapy for unexplained RPL, offering localized immune tolerance while avoiding systemic risks.
Read the full article.
Join the discussion in the comments:
- What challenges must be overcome for clinical translation?
- How might localised immune cloaking reshape patient care?
- Which biomarkers should guide future trials?
Explore the Special Collection: Immune Regulation and Inflammatory Mechanisms in Reproductive Health and Disease.”
Stay updated on all scientific advances in the field of fertility with Fertility News.
-
May 1, 2026, 03:13International Expert Recommendations in Emerging Reproductive Science – ESHRE
-
Apr 30, 2026, 18:45AI in Ultrasound Follicular Monitoring Moves Toward Clinical Decision Support – RBMO
-
Apr 30, 2026, 11:42ASRM Encourages Registration for Conference on Practice Growth and Innovation
-
Apr 30, 2026, 11:26ESHRE and ALPHA Launch Global Survey to Update ART Laboratory KPIs
-
Apr 30, 2026, 11:10Susanne Johnson: Advanced Gynaecology Ultrasound Course Day 2
-
Apr 30, 2026, 11:02Platelets Reduce Oxidative Stress Damage in Human Endometrial Stromal Cells in Vitro – RBMO
-
Apr 30, 2026, 10:57GREEG Day 2026: Elevate Your Ultrasound Expertise – GREEG
-
Apr 30, 2026, 10:49Up to Two-Thirds of Elite Female Athletes Experience Irregular Periods – Fertility Plus
-
Apr 30, 2026, 10:47Applications for the ESHRE5 Young Ambassadors 2026 are Still OPEN, But Not for Long! – ESHRE